That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
Matthew R Davis, Erin K McCreary, Jason M. Pogue
Abstract
Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Observational studySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicine2019-20 coronavirus outbreakRandomized controlled trialClinical trialAntiviral therapyVirologyInternal medicineVirusOutbreakDiseaseInfectious disease (medical specialty)Chronic hepatitisCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19